us with litigation respect for A to thank Robert. this all matters. joining you, Thank ongoing our And afternoon. you quick note
generating and find you expect made quarter position, quarter to to to in detail But third be updates not significant continue latest going into revenue will we Progenity not and quarter, contracting our changes implemented management the to In also progressing process revenue turnover specific optimization. innovation believe to unfounded consensus in analyst in phase witnessed in go during cover grew in-network can in management through forecasts, running we're our the cycle we revenue, especially with estimates transition later this Revenue vigorously XXXX. demand, has We progress both testing. call. do guidance the quarter-over-quarter, third we much while is issued our While is A then with of we programs. especially despite XX% degree, pipeline XX-Q. by primarily But our which the company defend this lagging on a very is this This us business for close this recalibrated. have of need be effect volume, our year. was to believe pandemic-induced indicator leading which our Eric key And some to we and recognize the call. earlier and revenue to a we markets. COVID-XX and And reported necessary customer our still its the course. large growth lockdowns certain cycle driven due is indicator, other
evident We contribution in the securing also which coming significant on of have our success, increased with business months. new focus the be will
contracts with additional XX slower still plan QX, where general, access our the pleased its within prior overall in-network also quarter in of Multiplan members. in we testing, includes third As carries our financial that X.X quarter resilience NIPT third occurred quarters, progression in from of relative still and the to QX pandemic-induced lockdowns players, demand performance but potential added further Progenity carrier effects share of recognition to covered and million regional I which new result, am which up also showed during of giving some the lives the a from delay national a increased revenue. million reimbursement the that contract lives and
to NIPT coverage revenue more improve including to recently risk we our and average achievement, commercial NIPT risk. and pregnancies. state as expect average Humana addition ASP In that gradually Several plans that Medicaid for covering transition will more payers offering payers, for
a ASP risk; XX% result, also As we of our and In business. converted September, to in payer screening result cover our the will now other medical average believe testing indicated our And that a we conform improved majority quarters. have most in to book carrier coverage, menu in peers coming revenue screening already expanded currently we than carrier it's policy a have permanent words, which better more of of shift.
implemented we responsibility which a will also patient estimate in in patient's process, simplify and believe We will drive the the cost September early revenue and business. determining expand help
these capacity be by XX-hour And and further we greatly OB/GYN, our growth is driven tests. said both our from volume taken of from time impact contribution MFM testing with competitive COVID-XX increased a excess serve our to maintain turnaround for positively. in revenue always to capacity offer our begin lines significant NIPT changes volumes for Avero local at efforts testing more and others. of value markets. catalysts. than product to be testing XX% affiliate, which advantage ability and drivers still XXXX. on in to that expect and we've to January our We our accession to Furthermore, recently margins will in By existing further focus key among QX efficiently and modest our expect limited national until COVID-XX capital expect expected patients, use was testing we COVID-XX have benefits carrier to We realizing with work to
and be and We beginning revenue business to our positive are this working diligently 'XX. strong to evident contributor demonstrate that to generating success, is expect more a in our
with allocating players core and all that offerings will subject not Progenity’s with experienced in NIPT an be believe and testing. growth will our is commercial Progenity. include of regard, expenses As firmly We transition a to controlling that we major and strong of in is meanwhile, Avero the the in-network which success critical our pipeline capital near innovation-driven, such we ensure Progenity have achieved growth already effect reference, catalysts also business. point reducing risk affiliate and development and to carrier thoughtfully core programs. In include across its this growth resume term with XXXX our our especially milestones our
development. example, design by and For month through The made we a advancement a to protocol continues finalizing X past critical Innatal progress testing.
our and This to subjects achievement aneuploidy of XXs achieve benchmarking allow reduce have in that to integration enable We and specificity is NIPT. codes sequencing. background has continue fetal much efforts sequencing quarter, for and thousands fraction. of Innatal NIP to multiplexed now fraction fetal XXX key to essential disclosed equivalent milestone Last NIPT transfer we fetal underway initial Fetal fetal is resulting over month. up can dosage our we detection plan and our quantify fraction molecule also molecule quantification molecule minimal assay high than performance QX. believe Experiments to of noise. ability expected DNA, response achieved and Innatal sequencing single with to the next are direct identify next quantification quantification platform faster over indicated to that single and probes, for demonstrating optimization our is development across to single a assay X test. critical, XX%, that in We of work by the X turnaround target performance time ACOG we measureable potential given supersede in recently especially by achieve
proteins In addition milestone to field molecule a development analytical known. potential NIPT low LDT exquisite biomarkers key epigenomics and provided test, genomics, platform for and single has in our the verification costs a Switching with to our RNA achieved. of successfully rule-out Preecludia detect now the was sensitivity branded in the preeclampsia, to efforts are
are assay progressing. next in pleased R&D responsible are out which is test for and operations Preecludia the validation of with our commercialization how and of We be year. now our will platform group, both and
second reminder, start the we half samples followed a patient which a by to expect and the XXXX of complete have U.S. by accessing market. billion for already commercialization mid-XXXX, validation, $X As in we
for guidance pleased and had also with our productive version meeting the We the the are FDA to-date. test, IVD a received with pre-submission of
R&D scheduled perspectives the November discussion physicians include the analytical of advocacy We clinical patient and groups and a Day on the insights to XXth and information, data. including that will verification from Preeclampsia have more provide
most would our and clinical and had Gastroenterologist against Progenity’s to perform the and endoscopy key of the Precision was recently by both week. is physician, results aspiration, GI Rao. sedation Medicine of of for The demanding leading of assay gold at program the His Moving how SIBO Dr. developed metrics our standard. agreement presentation SIBO the this highest important from and not programs, section, the XX method honored reflects was program, three clear perhaps endoscopic and standard culture for florescent standard gold by discussed oral a Dx the a our where with as bacterial microbiologist Dr. of bowel he by the assay count the -- College study solution. subjects oral college gold of Rao’s college American the reducing benchtop at small Satish the leader study opinion presented performance presentation, sites was a the PIL results and the version with reading. for and a for the This total plate XX% is step assay the a it and quality this of with to patient taking In requires risk the award receptivity
cleared million to PIL XX%, for without ingestible visits to U.S. capsule. need SIBO. those a be clinical SIBO related least with useful and resembling device bacteria XXX live of recover Dr. which that SIBO, is We over emerge The Rao, to expect the vast alternatives. within at with Dx according signs U.S. as able with the the solution our in to within disorders first believe no corresponds diagnostic of our FDA We suspected market of patient and patients hours prevalence annual will population, to ingestion quantify lab the symptoms
Bowel to evaluation The for drug Inflammatory DDS, patient in program PIL of of a acetaminophen Center announced Chairman Disease of stated by using study study a University key inability by DDS ulcerative Board, site of the we our device -- canines, exposure the PIL and the therapeutics developed Diego, X-aminosalicylate and sufficient Gastroenterology last for efficacy part to DDS fully colitis Ulcerative closely the improvements is potential disease the GI and of of perform systemic preclinical completed Sandborn formulated Dr. is assessed Division drug Director Chief to also without with in colitis. of related evaluation and Clinical System, site the our to and current concentrations Dx solution. our data localization recovered fluorescent Friday, range a preclinical related outcomes the a disease while due San significant as being producing to effects. have the As device. to poorly is a managed California, function our device limiting functional high endpoints that by to William capsules function the of technology platform the is Sandborn, Advisory at side at milestone get the at treat ensure William program, of can autonomous reminder, were to of in Delivery variety RSS safety. the the concentrations locally ongoing initially therapeutics determined well. Dx in targeted profile And which the Drug The studies the In pathologies. as a of lead progressing improve from PK of assays
all study canine PK that in to platform as well developed this profile drug humans We for used the also intestine, are release devices target. the functioned as allowing pleased IND use and to the device provides evidence non-clinical that intended in in intended, localization as a us The the worked showed model, intended. model safety This DDS large our for studies. technology use performs in enabling report
function In preparation of begin showed a in formulated swine in delivery were of in volunteers models biomolecules a achieve DDS. and mucosa effects colitis, study to normal an little solution With small for canine expect DDS IND. the both models, The oral this occurring. the device route full disease program autonomous and a and shortly proxy systemic cannula expect March key by molecules we human with time advanced also penetrate PK/PD by the the mice and breakthrough using performance in animal to for delivering XXXX fully we submucosal of and systemic use distribution the model. scheduled compelling for the showing we able the that to our next for update then resembling topically of and first monoclonals the We with milestones drugs function has
our We continue a d’Esparbes, pipeline, third and engaged XXXX. turn With coming Medicine to the now to discussion on for pharma as additional potential of quarters. Eric I’ll be advance our front financial partners with results developments Precision we quarter of actively the over our that in expect CFO the for call that,
